GCAM Inc.   Report issue

For profit Phase 3
Founded: Fullerton CA United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2020
NCT04142983
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

GCAM Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Tetanus (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1